Announcements

03FEB

Removal of Component(s) – DVAX

LifeSci Biotechnology Products Index Effective at the market close on February 5, 2025, DVAX will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On December 24, 2025, Dynavax Technologies announced it would be acquired by Sanofi for $15.50/share in cash.

08DEC

Semi-Annual Reconstitution (Preliminary) - December 2025

Please see attached PDF file for the preliminary changes to the LifeSci Biotechnology Clinical Trials Index and the LifeSci Biotechnology Products Index, scheduled to go into effect at the market open on 12/16/2025.

22OCT

Removal of Component(s) - AKRO, ETNB, MRUS, MTSR, TRML (Clinical Trials)

LifeSci Biotechnology Clinical Trials Index Effective at the market close on October 23, 2025, AKRO, ETNB, MRUS, MTSR and TRML will be removed from the LifeSci Biotechnology Clinical Trials Index and their values will be redistributed to the remaining index components based on their weights. Each of these companies have agreed to be acquired in all cash or mostly cash transactions.

27AUG

Removal of Component(s) - ITOS (Clinical Trials)

LifeSci Biotechnology Clinical Trials Index Effective at the market close on August 28, 2025, ITOS will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On July 21, 2025, iTeos Therapeutics announced it would be acquired by Concentra Biosciences for $10.047/share in cash plus a CVR (contingent value right).

17JUL

Removal of Component(s) - VERV (Clinical Trials)

LifeSci Biotechnology Clinical Trials Index Effective at the market close on July 23, 2025, VERV will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On June 17, 2025, Verve Therapeutics announced it would be acquired by Eli Lilly for $10.50/share in cash plus up to $3.00/share in a CVR (contingent value right).

09JUN

Semi-Annual Reconstitution (Preliminary) - June 2025

Please see attached PDF file for the preliminary changes to the LifeSci Biotechnology Clinical Trials Index and the LifeSci Biotechnology Products Index, scheduled to go into effect at the market open on 6/16/2025.

27MAR

Removal of Component(s) – ITCI

LifeSci Biotechnology Products Index Effective at the market close on March 27, 2025, ITCI will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On January 13, 2025, ITCI announced it agreed to be acquired for $132.00/share in cash.

09DEC

Semi-Annual Reconstitution (Preliminary) - December 2024

Please see attached PDF file for the preliminary changes to the LifeSci Biotechnology Clinical Trials Index and the LifeSci Biotechnology Products Index, scheduled to go into effect at the market open on 12/16/2024.

25NOV

Removal of Component(s) - LBPH (Clinical Trials)

LifeSci Biotechnology Clinical Trials Index Effective at the market close on November 26, 2024, LBPH will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On October 14, 2024, LBPH announced it agreed to be acquired for $60.00/share in cash.

13JUN

Semi-Annual Reconstitution (Final) - June 2024

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index Index Semi-Annual Reconstitution (Final) The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, June 17, 2024. All positions will be equally weighted, with weights determined as of the closing prices on Friday, June 14, 2024. The preliminary changes are summarized below. LifeSci Biotechnology Clinical Trials Index (120 components as adjusted) Additions (34 stocks): ABUS, ANNX, APLT, ARQT, AUTL, AVTE, CATX, CELC, CGON, CNTA, CRGX, DNTH, ELVN, ERAS, EWTX, FULC, HLVX, IMNM, JANX, KYTX, LBPH, LRMR, NAMS, NGNE, NUVB, PHVS, PRAX, PRME, SLN, STOK, SVRA,

29MAY

Removal of Component(s) – INBX

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Wednesday, May 29, 2024, INBX will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On January 23, 2024, Inhibrx announced that it would be acquired by Sanofi for $30.00/share in cash and one CVR for up to $5.00/cash.

15MAY

Removal of Component(s) – ALPN

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Thursday, March 16, 2024, ALPN will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On April 10, 2024, Alpine Immune Sciences announced that it would be acquired by Vertex Pharmaceuticals for $65.00/share in cash.

14MAR

Removal of Component(s) – CBAY, KRTX

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Friday, March 15, 2024, CBAY and KRTX will be removed from the LifeSci Biotechnology Clinical Trials Index and their values will be redistributed to the remaining index components based on their weights. On December 22, 2023, Karuna Therapeutics, Inc. announced that it would be acquired by Bristol Myers for $330.00/share in cash. On February 12, 2024, CymaBay announced that it would be acquired by Gilead Sciences for $32.50/share in cash.

05MAR

Removal of Component(s) – AMAM

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Wednesday, March 6, 2024, AMAM will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On January 8, 2024, Ambrx announced that it would be acquired by Johnson & Johnson for $28.00/share in cash.

20FEB

Removal of Component(s) – RYZB

LifeSci Biotechnology Clinical Trials Index Effective at the market close on Thursday, February 22, 2024, RYZB will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On December 26, 2023, RayzeBio, Inc. announced that it would be acquired by Bristol Myers for $62.50/share in cash.